$ARTH
Arch Therapeutics, Inc.

2015 Q3 Form 10-Q Financial Statement

#000114420415047254 Filed on August 07, 2015

View on sec.gov

Income Statement

Concept 2015 Q3 2015 Q2 2014 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.160M $810.0K $860.0K
YoY Change 34.88% -2.41%
% of Gross Profit
Research & Development $430.0K $525.1K $530.0K
YoY Change -18.87% 63.92%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00
YoY Change
% of Gross Profit
Operating Expenses $1.600M $1.338M $1.390M
YoY Change 15.11% 16.74% 44.79%
Operating Profit -$1.338M
YoY Change 16.74%
Interest Expense $410.0K $134.3K $2.020M
YoY Change -79.7% 383.83%
% of Operating Profit
Other Income/Expense, Net $0.00
YoY Change
Pretax Income -$1.100M -$770.0K $640.0K
YoY Change -271.88% -287.8% -166.67%
Income Tax $0.00
% Of Pretax Income 0.0%
Net Earnings -$1.100M -$772.4K $640.0K
YoY Change -271.88% -288.04% -166.67%
Net Earnings / Revenue
Basic Earnings Per Share -$0.02
Diluted Earnings Per Share -$11.07K -$0.02 $8.868K
COMMON SHARES
Basic Shares Outstanding 100.6M shares 76.80M shares 72.08M shares
Diluted Shares Outstanding 76.80M shares

Balance Sheet

Concept 2015 Q3 2015 Q2 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.960M $3.270M $830.0K
YoY Change 377.11% 81.67% 48.21%
Cash & Equivalents $3.960M $3.274M $833.5K
Short-Term Investments
Other Short-Term Assets $40.00K $40.00K $40.00K
YoY Change 0.0% 33.33% 100.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $4.003M $3.320M $877.0K
YoY Change 356.45% 80.95% -44.39%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $0.00
YoY Change -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change -100.0%
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $4.003M $3.320M $877.0K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $4.003M $3.320M $877.0K
YoY Change 356.45% 80.95% -44.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $231.8K $500.0K $175.8K
YoY Change 31.81% 201.18% -44.14%
Accrued Expenses $250.0K $480.0K $270.0K
YoY Change -7.41% 118.18% 92.86%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $470.0K $500.0K
YoY Change
Total Short-Term Liabilities $1.286M $1.890M $2.724M
YoY Change -52.78% -45.38% 497.81%
LONG-TERM LIABILITIES
Long-Term Debt $970.0K $960.0K $960.0K
YoY Change 1.04% 1.05% 2.13%
Other Long-Term Liabilities $210.0K $6.530M $4.090M
YoY Change -94.87% 22.74%
Total Long-Term Liabilities $1.177M $1.147M $5.046M
YoY Change -76.68% -81.72% 434.11%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.286M $1.890M $2.724M
Total Long-Term Liabilities $1.177M $1.147M $5.046M
Total Liabilities $2.463M $3.038M $7.769M
YoY Change -68.3% -68.78% 454.83%
SHAREHOLDERS EQUITY
Retained Earnings -$15.72M -$14.00M -$12.77M
YoY Change 23.07% 175.8%
Common Stock $17.26M $14.38M $5.882M
YoY Change 193.46% 19873.13% 9680.12%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.540M $279.4K -$6.892M
YoY Change
Total Liabilities & Shareholders Equity $4.003M $3.318M $877.0K
YoY Change 356.45% 80.84% -44.75%

Cashflow Statement

Concept 2015 Q3 2015 Q2 2014 Q3
OPERATING ACTIVITIES
Net Income -$1.100M -$772.4K $640.0K
YoY Change -271.88% -288.04% -166.67%
Depreciation, Depletion And Amortization $0.00 $0.00
YoY Change
Cash From Operating Activities -$1.610M -$820.0K -$970.0K
YoY Change 65.98% 10.81% 46.97%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $100.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.300M 3.520M 0.000
YoY Change -3620.0% -100.0%
NET CHANGE
Cash From Operating Activities -1.610M -820.0K -970.0K
Cash From Investing Activities 0.000
Cash From Financing Activities 2.300M 3.520M 0.000
Net Change In Cash 690.0K 2.700M -970.0K
YoY Change -171.13% -421.43% -1177.78%
FREE CASH FLOW
Cash From Operating Activities -$1.610M -$820.0K -$970.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3273764 USD
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
833520 USD
CY2015Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
6344817 USD
CY2014Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
3990000 USD
CY2015Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
7491377 USD
CY2014Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
5045766 USD
CY2015Q2 us-gaap Liabilities
Liabilities
9383266 USD
CY2014Q3 us-gaap Liabilities
Liabilities
7769433 USD
CY2015Q2 us-gaap Common Stock Value
CommonStockValue
92702 USD
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
72051 USD
CY2015Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
8566193 USD
CY2014Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
5810200 USD
CY2015Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-14624760 USD
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-12774694 USD
CY2015Q2 us-gaap Stockholders Equity
StockholdersEquity
-6065411 USD
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
-6892443 USD
CY2015Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3317855 USD
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
876990 USD
CY2015Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
498550 USD
CY2014Q2 us-gaap Revenues
Revenues
0 USD
CY2015Q2 us-gaap Revenues
Revenues
0 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2271443 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2536654 USD
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
320345 USD
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
525107 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
951101 USD
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
1146296 USD
us-gaap Interest Expense
InterestExpense
212647 USD
CY2014Q2 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
1557055 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
2013925 USD
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-1395245 USD
us-gaap Net Income Loss
NetIncomeLoss
-8777837 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0025 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0240 pure
CY2015Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
-925384 USD
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
2069693 USD
CY2015Q2 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-57016 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-5555293 USD
us-gaap Net Income Loss
NetIncomeLoss
-1850066 USD
CY2014Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.01
CY2015Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2014Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71949564 shares
CY2015Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76804674 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65933378 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75396047 shares
CY2014Q2 arth Gain On Exercise Of Warrants
GainOnExerciseOfWarrants
0 USD
arth Gain On Exercise Of Warrants
GainOnExerciseOfWarrants
299321 USD
CY2015Q2 us-gaap Derivative Loss On Derivative
DerivativeLossOnDerivative
-927373 USD
us-gaap Derivative Loss On Derivative
DerivativeLossOnDerivative
0 USD
us-gaap Derivative Loss On Derivative
DerivativeLossOnDerivative
996813 USD
CY2015Q2 arth Fair Value Of Derivative Liabilities In Excess Of Proceeds
FairValueOfDerivativeLiabilitiesInExcessOfProceeds
0 USD
CY2014Q2 arth Fair Value Of Derivative Liabilities In Excess Of Proceeds
FairValueOfDerivativeLiabilitiesInExcessOfProceeds
0 USD
arth Fair Value Of Derivative Liabilities In Excess Of Proceeds
FairValueOfDerivativeLiabilitiesInExcessOfProceeds
0 USD
arth Fair Value Of Derivative Liabilities In Excess Of Proceeds
FairValueOfDerivativeLiabilitiesInExcessOfProceeds
-7541693 USD
us-gaap Share Based Compensation
ShareBasedCompensation
748600 USD
us-gaap Share Based Compensation
ShareBasedCompensation
859627 USD
arth Noncash Interest Expense On Notes Payable
NoncashInterestExpenseOnNotesPayable
83295 USD
arth Noncash Interest Expense On Notes Payable
NoncashInterestExpenseOnNotesPayable
212332 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
77625 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
8625 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2515 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
621 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-148758 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
323850 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
75270 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
46069 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2379498 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2626756 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
1000000 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
3624703 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
5067000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1245205 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2440244 USD
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
557319 USD
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1802524 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1251000 USD
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-2069693 USD
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-2924064 USD
arth Change To Gain Or Loss On Warrant Modification
ChangeToGainOrLossOnWarrantModification
0 USD
arth Change To Gain Or Loss On Warrant Modification
ChangeToGainOrLossOnWarrantModification
-996813 USD
arth Non Cash Expense For Issuance Of Warrants
NonCashExpenseForIssuanceOfWarrants
0 USD
arth Non Cash Expense For Issuance Of Warrants
NonCashExpenseForIssuanceOfWarrants
7541693 USD
us-gaap Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
0 USD
us-gaap Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
92500 USD
arth Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
3066000 USD
arth Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
2624703 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
750000 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8637962 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2987500 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
515625 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
-8051432 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
11109837 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.34
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.19
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2015-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Registrant Name
EntityRegistrantName
Arch Therapeutics, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001537561
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Trading Symbol
TradingSymbol
ARTH
CY2015Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
100627241 shares
us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <u><font style="FONT-SIZE: 10pt">Use of Estimates</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <u><font style="FONT-SIZE: 10pt">Concentration of Credit Risk</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q2 us-gaap Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
454 USD
CY2014Q3 us-gaap Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
0 USD
CY2015Q2 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
100000 USD
CY2014Q3 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
0 USD
arth Issuance Of Inducement Of Shares
IssuanceOfInducementOfShares
0 USD
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
292860 USD
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
92702854 shares
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
72076487 shares
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
72076487 shares
CY2015Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2014Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2015Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76804674 shares
CY2014Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72084748 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75396047 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65933378 shares
us-gaap Depreciation
Depreciation
0 USD
us-gaap Depreciation
Depreciation
322 USD
arth Share Based Compensation Arrangement By Share Based Payment Award Options Awarded Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAwardedWeightedAverageRemainingContractualTerm
P0Y
arth Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm
P0Y
arth Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm
P0Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y4M10D
arth Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm
P4Y8M26D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P5Y4M10D
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
arth Share Based Compensation Arrangement By Share Based Payment Award Options Awarded Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAwardedAggregateIntrinsicValue
0 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0 USD
arth Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodAggregateIntrinsicValue
0 USD
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
292860 USD
arth Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodAggregateIntrinsicValue
160901 USD
arth Issuance Of Inducement Of Shares
IssuanceOfInducementOfShares
-100050 USD
CY2013Q2 arth Proceeds From Investors In Contemplation Of Merger
ProceedsFromInvestorsInContemplationOfMerger
2000000 USD
CY2013Q2 arth Unit Issued Price Per Share
UnitIssuedPricePerShare
0.50
CY2013Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.75
CY2013Q2 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
2000000 USD
CY2015Q1 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
0.20
CY2015Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
2765 USD
CY2014Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
8294 USD
CY2015Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
964060 USD
CY2014Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
955766 USD
CY2014Q4 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
224000 USD
CY2015Q1 arth Gain On Warrant Derivative Modification
GainOnWarrantDerivativeModification
624016 USD
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
451000 USD
CY2015Q2 arth Gain On Warrant Derivative Modification
GainOnWarrantDerivativeModification
927373 USD
arth Gain On Warrant Derivative Modification
GainOnWarrantDerivativeModification
896763 USD
arth Stock Issued During Period Inducement Shares
StockIssuedDuringPeriodInducementShares
435000 USD
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.35
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.31
arth Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
0.32
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
0.31
CY2015Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q2 arth Increase In Aggregate Number Of Shares
IncreaseInAggregateNumberOfShares
3000000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.766 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.194 pure
arth Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
0.00 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1257544 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.766 pure
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.194 pure
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0025 pure
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0240 pure
CY2015Q2 arth Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
0.00 pure
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2015Q2 us-gaap Derivative Fair Value Of Derivative Net
DerivativeFairValueOfDerivativeNet
927373 USD
CY2015Q3 arth Stock Issued During Period Inducement Shares
StockIssuedDuringPeriodInducementShares
570000 USD
CY2015Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
454387 shares
CY2015Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
100000 USD
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
454387 shares
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
100000 USD

Files In Submission

Name View Source Status
0001144204-15-047254-index-headers.html Edgar Link pending
0001144204-15-047254-index.html Edgar Link pending
0001144204-15-047254.txt Edgar Link pending
0001144204-15-047254-xbrl.zip Edgar Link pending
arth-20150630.xml Edgar Link completed
arth-20150630.xsd Edgar Link pending
arth-20150630_cal.xml Edgar Link unprocessable
arth-20150630_def.xml Edgar Link unprocessable
arth-20150630_lab.xml Edgar Link unprocessable
arth-20150630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tex10-3_logo.jpg Edgar Link pending
v416733_10q.htm Edgar Link pending
v416733_ex10-1.htm Edgar Link pending
v416733_ex10-3.htm Edgar Link pending
v416733_ex31-1.htm Edgar Link pending
v416733_ex31-2.htm Edgar Link pending
v416733_ex32-1.htm Edgar Link pending